Do proton pump inhibitors affect the effectiveness of cyclin-dependent kinase 4/6 inhibitors in advanced HR positive, HER2 negative breast cancer? A meta-analysis

• 主要な著者: Francisco Cezar Aquino de Moraes (著者), Caroline R. M. Pereira (著者), Vitor Kendi Tsuchiya Sano (著者), Estella Aparecida De Laia (著者), Carlos Stecca (著者), Rommel Mario Rodríguez Burbano (著者)
• フォーマット: 図書
• 出版事項: Frontiers Media S.A., 2024-05-01T00:00:00Z.
• 主題: article
• オンライン･アクセス: Connect to this object online.

Background:The CDK 4/6 inhibitors, including palbociclib and ribociclib, are the standard first-line treatment for hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer. Proton pump inhibitors are one of the most globally prescribed ty...